Abstract and key points
- Dichloroacetate (DCA) is a synthetic halogenated organic acid which has been used in rare diseases like congenital lactic acidosis.
- No controlled clinical trials of DCA are available.
- DCA is generally well tolerated; doses up to 6.25 mg/kg body weight twice daily can be administered safely to most subjects.
Dichloroacetate (DCA) is a substance that is being used for medical treatment of rare congenital forms of lactic acidosis, particularly pyruvate dehydrogenase complex (PDC) deficiency. The current interest in DCA as a cancer remedy evolved after the publication of a scientific article in 2007 that reported the ability of this compound to cause selective death of human cancer cells studied in tissue culture or after implantation into animal hosts. Subsequent claims by various non-scientific, for-profit groups were directed at the lay public regarding DCA’s purported anti-cancer effectiveness, based on results from the original pre-clinical studies and subsequent mostly unverifiable testimonials.
Following the initial report, several independent researchers have confirmed and extended the original findings of DCA’s anti-neoplastic activity in a variety of human cancer cells and animal models. These studies provide evidence that DCA interacts with fundamental metabolic and signalling pathways to inhibit malignant cell proliferation and could increase the effect of several anti-cancer substances.
No controlled clinical trials of DCA are available. The results of four small phase I trials, in which safety was the primary outcome, suggest that chronic administration of DCA as a single substance is generally well tolerated and might have effects against some human tumours. Though one study was terminated prematurely due to safety concerns, there is evidence that doses up to 6.25 mg/kg body weight twice daily can be administered safely to most subjects.
|Citation||Timm Hoeres, Markus Horneber, CAM-Cancer Consortium. Dichloroacetate [online document]. http://ws.cam-cancer.org/The-Summaries/Dietary-approaches/Dichloroacetate. July 13, 2016.|
- BG Chemie. Toxikologische Bewertung: Dichloressigsäure, Natriumdichloracetat. Toxikologische Bewertungen - Ausgabe 03/06 Nr. 188b, 1-138. 2006.
- Ammini, C. V. & Stacpoole, P. W. Biotransformation, Toxicology and Pharmacogenomics of Dichloroacetate. In : Gribble, G. W. (ed.), Naturally Occurring Organohalgoen Compounds – a Comprehensive Update. Berlin: Springer Verlag, 2003, pp. 215-34.
- Michelakis, E. D., Webster, L. & Mackey, J. R. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008;99:989-94.
- Stacpoole, P. W., Nagaraja, N. V. & Hutson, A. D. Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 2003;43:683-91.
- Chinnery, P., Majamaa, K., Turnbull, D. & Thornburn, D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006;1:CD004426.
- Stacpoole, P. W., Henderson, G. N., Yan, Z., Cornett, R. & James, M. O. Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev 1998;30:499-539.
- Agbenyega T, et al. Population kinetics, efficacy, and sadfety of dichloroacetate for lactic acidosis due to severe malaria in children. J Clin Pharmacol 2003;43:386-96.
- Kankotia, S. and P. W. Stacpoole. Dichloroacetate and cancer: new home for an orphan drug? Biochim Biophys Acta 2014;1846:617-29.
- Shroads, A. L. et al. Age-dependent kinetics and metabolism of dichloroacetate: possible relevance to toxicity. J Pharmacol Exp Ther 2008;324:1163-71.
- Shroads, A. L., T. Langaee, B. S. Coats, T. L. Kurtz, J. R. Bullock, D. Weithorn, Y. Gong, D. A. Wagner, D. A. Ostrov, J. A. Johnson and P. W. Stacpoole . Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate. J Clin Pharmacol 2012;52:837-49.
- Michelakis, E. D. et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010;2:1-7.
- James, MO & Stacpoole, PW. Pharmacogenetic considerations with dichloroacetate dosing. Pharmacogenomics 2016;17:743-53.
- Gorsky D. The latest chapter in the seemingly never-ending saga of dichloroacetate as a cancer treatmenthttps://www.sciencebasedmedicine.org/the-latest-chapter-in-the-seemingly-never-ending-saga-of-dichloroacetate-as-a-cancer-treatment/ (accessed on May 30, 2016)
- Geddes, L. Do-it-yourself Chemotherapy Access. Cancer World November/December, 2007;38-42.
- Warburg, O., Posener, K. & Negelein, E. Über den Stoffwechsel der Carcinomzelle. Biochem Ztschr 1924;152:309-44.
- Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
- Kim, J. W. & Dang, C. V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006;66:8927-30.
- Mathupala, S. P., Ko, Y. H. & Pedersen, P. L. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 2009;19:17-24.
- U.S. Food and Drug Administration. Search Orphan Drug Designations and Approvals (http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm [accessed on May 30, 2016].
- Garon, E. B., H. R. Christofk, W. Hosmer, C. D. Britten, A. Bahng, M. J. Crabtree, C. S. Hong, N. Kamranpour, S. Pitts, F. Kabbinavar, C. Patel, E. von Euw, A. Black, E. D. Michelakis, S. M. Dubinett and D. J. Slamon. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2014;140:443-52.
- Chu, Q. S., R. Sangha, J. Spratlin, J. V. L, J. R. Mackey, A. J. McEwan, P. Venner and E. D. Michelakis. A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors." Invest New Drugs 2015;33:603-10.
- Dunbar, E. M., B. S. Coats, A. L. Shroads, T. Langaee, A. Lew, J. R. Forder, J. J. Shuster, D. A. Wagner and P. W. Stacpoole. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest New Drugs 2014;32:452-64.
- Strum, S. B., O. Adalsteinsson, R. R. Black, D. Segal, N. L. Peress and J. Waldenfels. "Case report: Sodium dichloroacetate (DCA) inhibition of the "Warburg Effect" in a human cancer patient: complete response in non-Hodgkin's lymphoma after disease progression with rituximab-CHOP." J Bioenerg Biomembr 2013;45:307-15.
- Flavin, D. Medullary thyroid carcinoma relapse reversed with dichloroacetate: A case report. Oncol Lett 2010;1:889-91.
- Flavin, D. F. Non-Hodgkin's Lymphoma Reversal with Dichloroacetate. Volume 2010, Article ID 414726, 4 pages.
- Khan A. Use of oral dichloroacetate for palliation of leg pain arising from metastatic poorly differentiated carcinoma: a case report. J Palliat Med 2011;14:973-7.
- Calvert, L. D. et al. Dichloroacetate enhances performance and reduces blood lactate during maximal cycle exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:1090-4.
- Stacpoole, P. W. et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006;117:1519-31.
- Fox, A. W. et al. Reduction of serum lactate by sodium dichloroacetate, and human pharmacokinetic-pharmacodynamic relationships. J Pharmacol Exp Ther 1996;279:686-93.
- Krishna, S. et al. Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria. QJM 1995;88:341-9.
- Theodoratos, A. et al. Phenylalanine-induced leucopenia in genetic and dichloroacetic acid generated deficiency of glutathione transferase Zeta. Biochem Pharmacol 2009;77:1358-63.
- Stacpoole, P. W., Kurtz, T. L., Han, Z. & Langaee, T. Role of dichloroacetate in the treatment of genetic mitochondrial diseases. Adv Drug Deliv Rev 2008;60:1478-87.
- Kaufmann, P. et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006;66:324-30.
- Brandsma, D., Dorlo, T. P., Haanen, J. H., Beijnen, J. H. & Boogerd, W. Severe encephalopathy and polyneuropathy induced by dichloroacetate. J Neurol 2010;257:2099-100.
- Felitsyn, N., Stacpoole, P. W. & Notterpek, L. Dichloroacetate causes reversible demyelination in vitro: potential mechanism for its neuropathic effect. J Neurochem 2007;100:429-36.
- Heshe, D. et al. Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs. Cancer Chemother Pharmacol 2011;67:647-55.
- Stacpoole PW: The pharmacology of dichloroacetate. Metabolism 1989;38:1124-44.
The present documentation has been compiled by the CAM-CANCER Project with all due care and expert knowledge. However, the CAM-CANCER Project provides no assurance, guarantee or promise with regard to the correctness, accuracy, up-to-date status or completeness of the information it contains. This information is designed for health professionals. Readers are strongly advised to discuss the information with their physician. Accordingly, the CAM-CANCER Project shall not be liable for damage or loss caused because anyone relies on the information.